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A number of transporter proteins are expressed in the placenta, and they facilitate the pla-
cental transfer of drugs. The inhibition of P-glycoprotein (P-gp) was previously found to be
associated with an increase in the risk of congenital anomalies caused by drug substrates of
this transporter. We now explore the role of other placental transporter proteins.
Methods
A population-based case-referent study was performed using cases with congenital anoma-
lies (N = 5,131) from EUROCAT Northern Netherlands, a registry of congenital anomalies.
The referent population (N = 31,055) was selected from the pregnancy IADB.nl, a pharmacy
prescription database.
Results
Ten placental transporters known to have comparable expression levels in the placenta to
that of P-gp, were selected in this study. In total, 147 drugs were identified to be substrates,
inhibitors or inducers, of these transporters. Fifty-eight of these drugs were used by at least
one mother in our cases or referent population, and 28 were used in both. The highest user
rate was observed for the substrates of multidrug resistance-associated protein 1, mainly
folic acid (6% of cases, 8% of referents), and breast cancer resistance protein, mainly nitro-
furantoin (2.3% of cases, 2.9% of referents). In contrast to P-gp, drug interactions involving
substrates of these transporters did not have a significant effect on the risk of congenital
anomalies.
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Conclusions
Some of the drugs which are substrates or inhibitors of placental transporters were com-
monly used during pregnancy. No significant effect of transporter inhibition was found on
fetal drug exposure, possibly due to a limited number of exposures.
Introduction
Drug use in pregnancy raises many concerns about the risk of harmful effects on the foetus
while the use of these medications is inevitable to control certain medical conditions. The
potential harmful effects of drugs on the foetus are dependent upon, among others, the con-
centration of drug that reaches the foetal circulation, a factor which is partly modulated by pla-
cental transport of drugs.
A number of transporter proteins are expressed in the placenta to facilitate the transport of
biological substances to and from the foetus, including a subset of drugs [1–4]. This transport
can be modulated by interactions with other drugs transported by the same transporter. These
interactions may result in changes in substrate concentration in the foetal circulation without
affecting the maternal blood or plasma concentration of substrate drugs [5]. The effect of drug
interactions mediated by P-glycoprotein (P-gp), the most studied transporter protein, on foetal
drug exposure has been described earlier [6–11]. From our previous study, the risk of specific
foetal congenital anomalies was increased when the mothers used P-gp substrates in combina-
tion with other substrates or inhibitors [11].
To date, the effects of drug interactions mediated by other placental transporters were
observed only in in vitro studies [5,12,13]. Therefore, we aimed to describe the user rates of
drugs transported by placental transporters during the first trimester of pregnancy using popu-
lation-based databases. The second objective was to investigate the effect of drug interactions




Cases were selected from EUROCAT Northern Netherlands (NNL), a population-based regis-
try for children with congenital anomalies born in the Northern provinces of the Netherlands.
EUROCAT NNL registers foetuses or children with major congenital anomalies diagnosed
before or after birth, and up to 10 years old, upon consent for their parents. The information
available in the database includes sociodemographic characteristics of the parents and lifestyle
during pregnancy. The information on drug intake was obtained from pharmacy records and
then verified by a telephone interview with the mothers. Drug use was coded using the Ana-
tomical Therapeutic Chemical (ATC) codes, and noted either as prescribed or over-the-
counter (OTC).
Cases of major and minor congenital anomalies were classified according to EUROCAT
Subgroup of Congenital Anomalies version 2012 [14], the International Classification of Dis-
eases (ICD) coding system 9th revision for cases registered until 2001, and ICD 10th revision
for cases registered from 2002 onwards. We included only major anomalies: anomalies of the
nervous system, eye, ear, face & neck, heart, respiratory, oro-facial clefts, digestive system, uri-
nary, genital, and limb (Table A in S1 File).
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There are 6,059 cases, excluding cases with chromosomal anomalies, born between January
1, 1997 and December 31, 2013 and registered in EUROCAT NNL in March 2015. This num-
ber includes only those children whose mothers had a history of medication use at any time
during pregnancy in order to match with the referent population of drug users from the pre-
scription database. We excluded 572 cases with genetic disorders, i.e. microdeletion and
monogenic disorders. To avoid selection bias in drug prescribing, we included only the first
malformed child or pregnancy, which resulted in 5,131 cases.
Referent population sampling
The referent population was selected from IADB.nl, a population-based prescription database
in the Netherlands. IADB.nl holds the pharmacy data from about 600,000 people, covering
several parts of the country, mostly in the Northern provinces. The data were collected from
60 participating community pharmacies, and the prescription rates of the IADB.nl population
were found to be representative for the population in the Netherlands as a whole [15]. Pre-
scriptions registered in the database were prescribed by general practitioners or specialists,
which include the name of the drugs, the dispensing date, the ATC codes, dose and quantity
dispensed [15].
For studies on drug use in pregnancy, Pregnancy IADB.nl was constructed based on the
main IADB.nl, with linkage of prescription data of mother and child based on the coding of
home address. The date of conception was determined by assuming a gestational age 273 days
before the date of birth of the linked child. Twin or triplet pregnancies were excluded because
the gestation period is likely to be shorter than singleton pregnancies. Details of the linkage
and their validation are as reported earlier [16]. We selected children born within the same
time period as the cases, whose mothers were registered with complete information on drug
use. We then selected only the first registered pregnancy (N = 31,311) to avoid selection bias in
the drugs prescribed, since the drug selection may be influenced by the outcome of a previous
pregnancy. Since EUROCAT NNL and Pregnancy IADB.nl cover a similar geographical area,
it is possible that some children were registered in both databases. We therefore excluded 256
children (0.8% out of 31,311) from the Pregnancy IADB.nl, because the birth dates of the
mothers and children, and the gender of the child matched with the children in EUROCAT
NNL.
Drug exposure definitions
Selection of placental transporters proteins and drug substrates. Our previous study
showed that P-gp inhibition was associated with an increased risk of congenital anomalies
caused by drug substrates of P-gp, suggesting the importance of this transporter in foetal drug
exposure [11]. Therefore, in this study, we included all other placental transporters that have a
mRNA expression level in the placenta at least comparable to that of P-gp, which is 0.0255 as a
ratio of the expression of peptidylprolyl isomerase (PPIA) mRNA, a housekeeping gene [17–
19]. From these transporters, protein expression of BCRP, OCT3, OAT4 and OATP2B1 was
detected in the first trimester placenta so far [20–22]. The protein expression of BCRP
increases throughout gestation but later decreases within the third trimester, while OCT3 is
moderately increased throughout gestation [21,23,24]. OAT4 and OATP2B1 were found to be
expressed in the placenta of early pregnancy, although the changes in the expression through-
out gestation were not much reported [25,26]. For the other transporters, we found no data
regarding the protein expression in the placental layer in the first trimester of pregnancy.
The selection of drug substrates of the transporters is based on review articles that report
the results from in vitro and in vivo studies [3,5,27–30]. The articles were searched in PubMed
Placental transporters and transporter-mediated drug interactions
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using combinations of these keywords: "placenta", "drug transporters", "drug substrate", "drug
inhibitor", "Breast Cancer Resistance Protein", "ABCG2", "Multidrug resistance-associated
proteins", "MRP1", "Organic anion transporters", "OAT4", "OATP2B1", "OCT3", "Monocar-
boxylate transporters”, "MCT1", "MCT4", "MCT8", "MCT10", "equilibrative nucleoside trans-
porters", and "ENT1". These drugs were classified according to substrate affinity to each
placental transporter, including substrate, substrate/inhibitor, inhibitor, substrate/inducer and
inducer, as previously done [11].
User rates of drugs associated with placental transporters. For the first objective, we
described the user rates of drugs associated with transporter proteins between cases and refer-
ent population. User rates were defined as the self-reported use of (in cases), or the pharmacy
dispensing of (in referent population) the selected drugs, from three months before the esti-
mated conception date through the first three months of pregnancy. We included the precon-
ception period because the drugs may be continually used during the first trimester of
pregnancy, for the referent population. The use of OTC drugs was disregarded because the
Pregnancy IADB.nl does not register the use of these drugs. However, prescribing regulations
for ranitidine, ibuprofen and aspirin changed in the Netherlands during the study period, as
reported by the Medicines Evaluation Board of the Netherlands. Therefore, we only included
the use of prescribed ranitidine, ibuprofen and aspirin among cases. Since folic acid is usually
taken as an OTC medication, its use was also included only when it was prescribed.
Drug interactions and the risk of congenital anomalies. For the second objective, we
explored the effect of drug-drug interactions involving placental transporter proteins on the
risk of foetal teratogenicity. We assessed the risk of overall congenital anomalies with the use
of all substrates of each placental transporter. The analyses were performed for individual
transporters, as fetal drug exposure may depend upon whether the influx or efflux has
changed, and the localization of the transporters. Since breast cancer resistance protein
(BCRP) is known to be involved in a vectorial transport with organic anion transporting poly-
peptide 2B1 (OATP2B1) [1], we also determined the effect of drug interactions involving the
substrates of both placental transporters.
Statistical analysis
The user rates of the selected drugs were calculated by using the total number of cases or the
population as the denominator. For the drug interaction study, binary logistic regression was
used to calculate odds ratios (OR) and 95% confidence intervals for the risk of anomalies with
each drug interaction pattern. Analyses were performed using PSAW Statistics, Version 22
(IBM Corporation, Armonk, NY, USA).
Results
Selection of placental transporters and drug substrates
Our study focused on placental transporters that have comparable expression levels to P-gp in
the placenta, and we have identified ten eligible placental transporters: breast cancer resistance
protein (BCRP) and multidrug resistance-associated protein 1 (MRP1) as efflux transporters,
and organic cation transporter 3 (OCT3), equilibrative nucleoside transporter (ENT1), organic
anion transporter 4 (OAT4), organic anion transporting polypeptide 2B1 (OATP2B1) and
monocarboxylate transporters 1, 4, 8 and 10 (MCT1, MCT4, MCT8, MCT10) as influx trans-
porters. The localizations of these transporters in placental tissue and the direction of substrate
transport are as summarized in Fig 1, although the exact localization for some transporters is
not very clear [1–4,30–36].
Placental transporters and transporter-mediated drug interactions
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Fig 1. Placental transporter proteins are expressed on either side of the placenta. Five transporter proteins are expressed in the apical
(maternal-facing) layer of placental cells, which include breast cancer resistance protein (BCRP), equilibrative nucleoside transporter (ENT),
monocarboxylate transporter 4, 8, 10 (MCT4, MCT8, MCT10). Another five are expressed in the basolateral (fetal-facing) layer of placental
cells, including multidrug resistance-associated protein (MRP), organic cation transporter 3 (OCT3), organic anion transporter 4 (OAT4),
organic anion transporting polypeptide 2B1 (OATP2B1) and monocarboxylate transporter 1 (MCT1). The arrows show the direction of
substrate transport through the cells.
https://doi.org/10.1371/journal.pone.0173530.g001
Placental transporters and transporter-mediated drug interactions
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From the literature, 168 drugs are classified to be associated with the transport of these pla-
cental transporters, either as substrates, inducers or inhibitors. We excluded 21 of these drugs
because they are either experimental or veterinary drugs, or without ATC codes. There were a
total of 147 drugs selected to investigate the first objective: 53 drugs associated with BCRP
transport, 45 drugs with OCT3, 29 drugs with OAT4, 28 drugs with MRP1, 24 drugs with
OATP2B1, 8 drugs with ENT1, 10 drugs with MCT1, 6 drugs with MCT4, and 3 drugs with
both MTC8 and MCT10 (one drug may be associated with the transport of more than one
transporter). The list of all placental transporters included in this study and their respective
drug substrates, inducers and inhibitors can be found in Table C in S1 File.
User rates of drugs associated with placental transporters among cases
and the referent population
Characteristics of children born to case mothers and to mothers in the referent population are
shown in Table 1. The mothers in the case group were slightly older than the mothers in the
referent population (30.2 ± 4.6 years and 29.5 ± 4.9 years, respectively, p< 0.01). The majority
of cases were liveborn while all the children in the referent population were liveborn. The most
common types of anomalies among the case group were heart and limb anomalies (around
25% each), followed by anomalies in the digestive system (12.3%).
Out of 147 drugs associated with placental transporters, 58 were used by at least one mother
in either the cases or the referent population, as listed in Table 2. Only 28 of the drugs were
used by at least one mother in both groups. Table 3 shows the percentage of mothers who used
at least one of the drugs, according to their substrate specificity to each placental transporter
protein. Drugs classified to be substrates/inducers or inducers of these transporters were not
found to be used by our study populations. The use of MRP1 drug substrates was more com-
mon as compared to substrates of other transporters; it was observed in 6% of the case mothers
and 8% of the referent population. The highest user rate was for folic acid (prescribed), as one
of the substrates of MRP1. BCRP substrates were used in 3% and 3.6% of the case and referent
population, respectively. The percentage resulted largely from the use of nitrofurantoin (2.3%
and 2.9% in cases and referent population, respectively). Restricting the analysis for liveborn
cases only showed a slight reduction in user rates for each transporter (Tables 2 and 3).
Placental transporter-mediated drug interactions and the risk of
congenital anomalies
Drug interaction analysis can only be done for MRP1, BCRP and MCT1 substrates (Table B in
S1 File). There were no users of OCT3, OAT4, OATP2B1 and MCT4 substrates in combina-
tion with an inhibitor to calculate the OR. Due to limited sample size, we were not able to
show any significant increase in the risk of congenital anomalies with the use of drugs trans-
ported by each transporter in combination with the inhibitors.
Discussion
Placental transporters may potentially play a role in foetal drug transfer in view of the vast
range of drugs transported by these transporters. Ten placental transporter proteins were
selected based on their mRNA expression profile in the placenta, since the data on the protein
expression during early pregnancy were scarce. As our focus is drug teratogenicity, the expres-
sion of these transporters during early fetal development is of major interest. Therefore, the
mRNA expression profile was taken as an indicator of their protein expression during this
period. For ten placental transporters included in this study, 28 drugs were reported in in-vitro
Placental transporters and transporter-mediated drug interactions
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or ex-vivo studies to be substrates or inhibitors, and these were used by at least one pregnant
woman in both the case group and the referent population. For each placental transporter, the
number of mothers who used drug substrates were generally lower than for P-gp, (the use of
P-gp drug substrates was 10% in cases and 12% in the referent population) [11]. This is proba-
bly because the substrates for those transporters are much less studied and therefore much less
is known about them as compared to P-gp substrates.
Knowledge about the expression of most of the placental transporters in this study is rela-
tively new, and their contribution to drug transport in the placenta has not been completely
characterized. Despite that, transporter-mediated drug interactions can potentially cause clini-
cally relevant changes in drug pharmacokinetics and drug exposure, as previously observed for
P-gp, BCRP and MRPs [5,36]. In this study, we did not find significant changes in the risk for
congenital anomalies by inhibitors of the placental transporters studied, possibly due to the
Table 1. Characteristics of children born to case mothers and referent population mothers.
Characteristics Cases (N = 5,131) Referent population (N = 31,055)
Maternal age at delivery*, mean years ± s.d 30.2 ± 4.6 29.5 ± 4.9
Gender, N (%)
Boy 2,864 (55.8) 16,064 (51.7)
Girl 2,259 (44.0) 14,991 (48.3)
Missing data 8 (0.2) -
Year of birth, N (%)
1997–1998 665 (13.0) 5,736 (18.5)
1999–2000 695 (13.5) 5,492 (17.7)
2001–2002 634 (12.4) 4,551 (14.7)
2003–2004 620 (12.1) 3,954 (12.7)
2005–2006 637 (12.4) 3,247 (10.5)
2007–2008 576 (11.2) 2,927 (9.4)
2009–2010 658 (12.8) 2,805 (9.0)
2011–2012 527 (10.3) 1,983 (6.4)
2013 119 (2.3) 360 (1.2)
Type of birth, N (%)
Live birth 4,805 (93.6) 31,055 (100.0)
Termination of pregnancy 224 (4.4) 0
Stillbirth 65 (1.3) 0
Miscarriage (>24 weeks) 37 (0.7) 0
Types of anomaliesa, N (%)
Heart 1,377 (26.8) -
Limb 1,228 (23.9) -
Digestive 633 (12.3) -
Urinary 563 (11.0) -
Clefts 457 (8.9) -
Genital 444 (8.7) -
Central nervous system 383 (7.5) -
Eye, ear, face and neck 175 (3.4) -
Respiratory 91 (1.8) -
*p-value < 0.01;
s.d: standard deviation;
acases with multiple congenital anomalies are represented in more than one anomaly group
https://doi.org/10.1371/journal.pone.0173530.t001
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limited number of users in each drug interaction pattern. Furthermore, there were potential
biases that might affect the risk estimates. First, we only considered the use of prescribed folic
acid, because the data on OTC medications were not available in the prescription records.
However, we assumed a comparable rate of non-prescribed folic acid between the case group
and the referent population, which might have led to a non-differential bias on our risk
estimates.
There are also several other factors that should be taken into consideration in interpreting
the role of placental transporters in the foetal drug exposure. First, the same efflux and influx
transporters are also present in other tissues (i.e. intestine and liver), which are important for
the distribution and elimination of their substrates. Drug interactions in these tissues, apart
from the placenta, may affect substrate exposure to the fetus. However, these interactions did
not warrant pharmacovigilance measures so far, therefore we do not expect these interactions
to have a significant impact on our results. Second, there is high inter-individual variation in
the expression of these transporters due to genetic variability in the genes encoding for them
[4,12]. Genotype-dependent transporter-mediated drug interactions have not yet been well
studied, but the effect was already observed for fexofenadine and OATP2B1 inhibition [37],
and for metformin and OCT2 inhibition [38]. Third, drug pharmacokinetics in the maternal
circulation are also altered during pregnancy due to normal physiological changes [31,39], and
possible drug-drug interaction involving metabolic enzymes, i.e. CYP450. However, using the
software-supported medications surveillance system in the Netherlands, these interactions
may have been avoided during the prescribing and dispensing process. Therefore, we assumed
that, at least from 2002, the clinically significant CYP-mediated drug interactions had already
been avoided [40]. Fourth, placental transporters often have broad and overlapping substrate
specificities, and the net effect of drug interactions involving substrates with more than one
transporter is difficult to measure.
Our study has several strengths and limitations. One of the strengths is that the information
on drug use was well documented in both databases. Duration of drug use is well documented
Table 3. User rates of drugs associated with placental transporter in the first trimester of pregnancy among cases and referent population.
Placental
transporters

























BCRP 153 (3.0) 137 (2.9) 1,131 (3.6) 0 0 2 (0.01) 49 (1.0) 44(0.92) 302 (1.0)
OCT3 0 0 10 (0.03) 56 (1.1) 53 (1.1) 480 (1.5) 72 (1.4) 67 (1.4) 303 (1.0)
OAT4 0 0 0 24 (0.47) 21 (0.44) 60 (0.19) 3 (0.06) 2 (0.04) 28 (0.09)
MRP1 307 (6.0) 288 (6.0) 2471 (8.0) 0 0 2 (0.01) 8 (0.16) 8 (0.17) 21 (0.07)
OATP2B1 0 0 3 (0.01) 9 (0.18) 9 (0.19) 100 (0.32) 4 (0.08) 4 (0.08) 25 (0.08)
ENT1 0 0 0 0 0 0 0 0 5 (0.02)
MCT1 25 (0.55) 21 (0.44) 48 (0.15) 0 0 0 63 (1.2) 59 (1.2) 857 (2.8)
MCT4 20 (0.39) 17 (0.35) 29 (0.09) 0 0 0 5 (0.10) 5 (0.10) 32 (0.10)
MCT8 &
MCT10*
0 0 0 0 0 0 0 0 3 (0.01)
BCRP: breast cancer resistance protein; OCT: organic cation transporter; OAT: organic anion transporter; MRP: multidrug-associated protein; OATP:
organic anion transporting polypeptide; ENT: equilibrative nucleoside transporter; MCT: monocarboxylate transporter;
#same mother who used more than one drug that belongs to the same substrate classification was counted once;
*same drug substrates for both transporters
https://doi.org/10.1371/journal.pone.0173530.t003
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with minimal recall bias, and the inclusion of mother-children pair was done over the same
period of years. Further, our study is among the first to investigate the role of transporter pro-
teins in the placenta using a population-based study. Our knowledge of foetal transfer of drugs
was previously based on in vitro studies using cell lines and ex vivo placental models, which do
not take into consideration the other clinical parameters involved [35,41]. Moreover, limited
methods can be used to study the role of transporters in the early stage of pregnancy, which is
a crucial period for foetal development.
One limitation of our study is the potential for misclassification of drug exposure in the pre-
scription database (Pregnancy IADB.nl) because we cannot be sure that the mothers actually
took the drugs dispensed. Further, the period of exposure was an estimation calculated from
the date of delivery with the assumption of 273 days of gestation. If the mothers were classified
as exposed when they were not, it would lead to an underestimation of the observed risk.
Another limitation is that the mRNA expression, instead of protein level, is used in the selec-
tion of placental transporters, and the assumption of drug interactions at the placenta is based
on drugs prescribed and not on measured drug concentrations. The list of drug substrates
reported by the literature might not be complete and the substrate classification might also
depend on the concentration of the respective drug. Moreover, the substrate specificity of
many transporters is broad and not very well studied for placental transporters. Confounding
by indication is also impossible to address because nothing is known in our databases about
the medical condition for which the drug was prescribed and used. Finally, as acknowledged
earlier, despite a large number of cases and referents, due to a wide variety of exposures, we
had limited power to detect statistically significant effects.
In conclusion, we classified drugs based on their substrate specificity to several placental
transporter proteins, and described the use of these drugs during the first trimester of preg-
nancy. Using the same approach as in our previous study on P-gp, we were unable to find a
significant association between the inhibition of these transporters and the risk of congenital
anomalies. We did not have enough power to draw conclusions on the causality, and larger
databases are needed to answer this question. However, the list of substrates for each trans-
porter may not be complete, and therefore the effect of drug interactions may be underesti-
mated. Nonetheless, knowledge about transporter-mediated drug interactions in the placenta
is clearly important for drugs with known risk of teratogenicity. Larger-scale databases are
needed in the future to further denote the role of these transporters in foetal drug transport.
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